Author: Lucchini, Matteo; Bianco, Assunta; Giacomo, Paola Del; De Fino, Chiara; Nociti, Viviana; Mirabella, Massimiliano
Title: Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report Cord-id: d0kf9gme Document date: 2020_6_22
ID: d0kf9gme
Snippet: The emergency represented by the COVID-19 pandemic represents a new challenge for clinicians who deal with autoimmune diseases because of patients undergoing immunosuppressive therapy. Few cases of Multiple Sclerosis (MS) patients receiving ocrelizumab who contracted COVID-19 with a benign course have recently been published. We present the case of a MS patient with mild COVID-19 who developed SARS-CoV-2 specific IgA without IgG ten weeks after infection. Patients on B-cell depleting drugs have
Document: The emergency represented by the COVID-19 pandemic represents a new challenge for clinicians who deal with autoimmune diseases because of patients undergoing immunosuppressive therapy. Few cases of Multiple Sclerosis (MS) patients receiving ocrelizumab who contracted COVID-19 with a benign course have recently been published. We present the case of a MS patient with mild COVID-19 who developed SARS-CoV-2 specific IgA without IgG ten weeks after infection. Patients on B-cell depleting drugs have a reduced antibody immune response to viral neoantigens. A relative sparing of mucosal-associated lymphoid tissues (MALT) could be responsible for IgA response in our patient.
Search related documents:
Co phrase search for related documents- low undetectable and lymphoid tissue: 1
Co phrase search for related documents, hyperlinks ordered by date